emavusertib (CA-4948) is a Curis Inc program in frontline chronic lymphocytic leukemia. Its next catalyst is a Readout in Dec 2026.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Frontline chronic lymphocytic leukemia. Sponsor: Curis Inc (CRIS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for emavusertib (CA-4948) is a Readout in Dec 2026.
No FDA decision for emavusertib (CA-4948) is in our archive yet.
In our records emavusertib (CA-4948) is under review or in development for Frontline chronic lymphocytic leukemia.
Curis Inc (CRIS).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.